Selegiline Hydrochloride Articles
Valeant slumps into 3rd-qtr $12M loss
12 November 2007
Stock Commentary - New York week to September 24, 2007
27 September 2007
Valeant's 2nd-qtr 2007 income stays constant
13 August 2007
Valeant launches Zelapar in USA
24 July 2006
Valeant moves closer to Zelapar approval
17 January 2005
Amarin Corp sees revenues plunge
5 April 2004
Amarin completes asset sale to Valeant
1 March 2004
Valeant buys Amarin unit in $38M deal
23 February 2004
Permax competition slashes Amarin sales
18 August 2003
Elan gains $89.5M from Xcel investment
7 April 2003
Amarin's Zelapar approvable in USA
24 February 2003
Amarin acquires USA rights to Permax
15 July 2002
Recent developments in drug delivery - by Mark Greener
19 January 2000
Athena's Zelapar Launched In UK
9 December 1998
Elan's Combi Nicotine Patch A Partial Success
24 November 1998
Showing 1-15 of 15 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
